Biotech News

Kura Oncology to Participate in Two Investor Conferences in November

Kura Oncology (KURA)Kura OncologyConference / presentation

SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: UBS Global Biopharma London Conference

Related news

Kura Oncology

Precision Oncology Company Kura Oncology develops and commercializes small-molecule therapies for genetically defined cancers. Its portfolio focuses on menin inhibition in hematologic malignancies and farnesyl-transferase inhibition in solid tumors. KOMZIFTI KOMZIFTI, or ziftomenib, is an FDA-approved oral menin inhibitor for adults with...

Recent company news

Stock data

Close
7.35 USD
Market cap
796.31M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States